ATP6V1C2

Across TCGA pan-cancer cohorts, ATP6V1C2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ATP6V1C2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ATP6V1C2 RNA is repressed in tumor relative to normal tissue. In most cancer types ATP6V1C2 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and COAD are the cancer types where ATP6V1C2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP6V1C2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−3.157	<.001	12	view →
KIRP	Male	All	−3.617	<.001	11	view →
COAD	Male	IV	+2.114	<.001	11	view →
HNSC	Male	II,III,IV	−1.593	<.001	11	view →
LUAD	Male	II,III,IV	+1.181	<.001	9	view →
UCEC	All	III,IV	+2.307	<.001	8	view →
LIHC	Female	II,III,IV	+0.621	<.001	8	view →
LUSC	Male	II,III,IV	+1.558	<.001	7	view →
BLCA	Male	All	+1.016	.001	7	view →
CHOL	All	All	+1.807	<.001	4	view →
READ	All	All	+1.018	.002	2	view →
PRAD	All	All	−0.690	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ATP6V1C2–KIRC

Open the KIRC breakdown →